Richard A. Larson to Lymphoma
This is a "connection" page, showing publications Richard A. Larson has written about Lymphoma.
Connection Strength
0.998
-
Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma. Curr Hematol Malig Rep. 2023 Dec; 18(6):217-225.
Score: 0.815
-
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol. 2014 Apr; 165(1):102-11.
Score: 0.105
-
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17.
Score: 0.020
-
Psychosocial symptomatology, personal growth, and development among young adult patients following the diagnosis of leukemia or lymphoma. J Clin Oncol. 1988 Apr; 6(4):613-7.
Score: 0.018
-
Hypercalcemia and lytic bone lesions in a patient with B-cell non-Hodgkin's lymphoma. N Engl J Med. 1984 Jan 26; 310(4):263-4.
Score: 0.013
-
Polymorphisms in the MLL breakpoint cluster region (BCR). Hum Genet. 2003 Jul; 113(1):80-91.
Score: 0.012
-
Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood. 1993 Dec 15; 82(12):3705-11.
Score: 0.007
-
Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation. Bone Marrow Transplant. 1992 Jan; 9(1):41-7.
Score: 0.006
-
Nonrandom chromosome abnormalities in angioimmunoblastic lymphadenopathy. Blood. 1982 Oct; 60(4):877-87.
Score: 0.003